New mechanisms and modalities emerge for TIGIT

It’s been relatively quiet for TIGIT since the next-generation checkpoint made a big splash at ASCO20, but as industry has been waiting for new data to drop from the leading programs, other companies have been stretching the possible plays in TIGIT with new modalities and original applications. 

The Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH) conferences, though short on clinical data for therapies targeting TIGIT, highlight a series of new modalities, mechanisms, indications and applications for the checkpoint across nearly 50 abstracts combined. ...